TP53 and neoplasm: Furthermore, MSCs pretreated with cisplatin altered the phosphorylation state of several tyrosine kinases, such as WNK1, c-Jun, STAT3 and p53, and produced factors that turn on the changes in stemness and resistance of tumor cells, thus promoting therapeutic resistance of tumor cells [99] (Table 2).